Kristina M Rabarison1, Rui Li2, Connie L Bish3, Robin C Vanderpool4, Richard A Crosby5, Mehran S Massoudi6. 1. Centers for Disease Control and Prevention, krabarison@cdc.gov. 2. Division of Diabetes Translation, Centers for Disease Control and Prevention, RuiLi@cdc.gov. 3. Division of Population Health, Centers for Disease Control and Prevention, aez2@cdc.gov. 4. University of Kentucky, robin@kcr.uky.edu. 5. University of Kentucky, richard.crosby@uky.edu. 6. Division of Population Health, Centers for Disease Control and Prevention, mrm8@cdc.gov.
Abstract
BACKGROUND: Cervical cancer places a substantial economic burden on our healthcare system. The three-dose human papillomavirus (HPV) vaccine series is a cost-effective intervention to prevent HPV infection and resultant cervical cancer. Despite its efficacy, completion rates are low in young women aged 18 through 26 years. 1-2-3 Pap is a video intervention tested and proven to increase HPV vaccination completion rates. PURPOSE: To provide the full scope of available evidence for 1-2-3 Pap, this study adds economic evidence to the intervention's efficacy. This study tested the economies of scale hypothesis that the cost of 1-2-3 Pap intervention per number of completed HPV vaccine series would decrease when offered to more women in the target population. METHODS: Using cost and efficacy data from the Rural Cancer Prevention Center, a cost analysis was done through a hypothetical adaptation scenario in rural Kentucky. RESULTS: Assuming the same success rate as in the efficacy study, the 1-2-3 Pap adaptation scenario would cover 1000 additional women aged 18 through 26 years (344 in efficacy study; 1346 in adaptation scenario), and almost three times as many completed series (130 in efficacy study; 412 in adaptation scenario) as in the original 1-2-3 Pap efficacy study. IMPLICATIONS: Determination of the costs of implementing 1-2-3 Pap is vital for program expansion. This study provides practitioners and decision makers with objective measures for scalability.
BACKGROUND:Cervical cancer places a substantial economic burden on our healthcare system. The three-dose human papillomavirus (HPV) vaccine series is a cost-effective intervention to prevent HPV infection and resultant cervical cancer. Despite its efficacy, completion rates are low in young women aged 18 through 26 years. 1-2-3 Pap is a video intervention tested and proven to increase HPV vaccination completion rates. PURPOSE: To provide the full scope of available evidence for 1-2-3 Pap, this study adds economic evidence to the intervention's efficacy. This study tested the economies of scale hypothesis that the cost of 1-2-3 Pap intervention per number of completed HPV vaccine series would decrease when offered to more women in the target population. METHODS: Using cost and efficacy data from the Rural Cancer Prevention Center, a cost analysis was done through a hypothetical adaptation scenario in rural Kentucky. RESULTS: Assuming the same success rate as in the efficacy study, the 1-2-3 Pap adaptation scenario would cover 1000 additional women aged 18 through 26 years (344 in efficacy study; 1346 in adaptation scenario), and almost three times as many completed series (130 in efficacy study; 412 in adaptation scenario) as in the original 1-2-3 Pap efficacy study. IMPLICATIONS: Determination of the costs of implementing 1-2-3 Pap is vital for program expansion. This study provides practitioners and decision makers with objective measures for scalability.
Entities:
Keywords:
HPV vaccine; cervical cancer; cost analysis; economic evaluation; prevention research center
Authors: Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz Journal: Vaccine Date: 2012-08-04 Impact factor: 3.641
Authors: Robin C Vanderpool; Elisia Cohen; Richard A Crosby; Maudella G Jones; Wallace Bates; Baretta R Casey; Tom Collins Journal: J Commun Date: 2013-01-10